InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) and PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|InVivo Therapeutics Holdings Corp.||1||0.00||N/A||-8.46||0.00|
|PhaseBio Pharmaceuticals Inc.||9||158.20||N/A||4.52||1.73|
Table 1 shows top-line revenue, earnings per share and valuation of the two companies.
Table 2 has InVivo Therapeutics Holdings Corp. and PhaseBio Pharmaceuticals Inc.’s net margins, return on assets and return on equity.
|Net Margins||Return on Equity||Return on Assets|
|InVivo Therapeutics Holdings Corp.||0.00%||-184.1%||-105.5%|
|PhaseBio Pharmaceuticals Inc.||0.00%||0%||0%|
6.9 and 6.9 are the respective Current Ratio and a Quick Ratio of InVivo Therapeutics Holdings Corp. Its rival PhaseBio Pharmaceuticals Inc.’s Current and Quick Ratios are 14.2 and 14.2 respectively. PhaseBio Pharmaceuticals Inc. has a better chance of clearing its pay short and long-term debts than InVivo Therapeutics Holdings Corp.
Insider and Institutional Ownership
Institutional investors owned 12.4% of InVivo Therapeutics Holdings Corp. shares and 57.7% of PhaseBio Pharmaceuticals Inc. shares. About 0.1% of InVivo Therapeutics Holdings Corp.’s share are owned by insiders. Competitively, 0.4% are PhaseBio Pharmaceuticals Inc.’s share owned by insiders.
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|InVivo Therapeutics Holdings Corp.||16.11%||-14.81%||-52.12%||-60.95%||-69.49%||-56.56%|
|PhaseBio Pharmaceuticals Inc.||-16.74%||-43.73%||-40.97%||120%||0%||152.75%|
For the past year InVivo Therapeutics Holdings Corp. has -56.56% weaker performance while PhaseBio Pharmaceuticals Inc. has 152.75% stronger performance.
PhaseBio Pharmaceuticals Inc. beats on 8 of the 8 factors InVivo Therapeutics Holdings Corp.
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, focus on developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for acute SCI; and Therapeutic Trails injection program for the treatment of chronic SCI. The company was founded in 2005 and is headquartered in Cambridge, Massachusetts.
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. It is also developing PB1046, a fusion protein currently in a Phase 2b clinical trial for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is based in Malvern, Pennsylvania.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.